Teva Ends Development of Fremanezumab in Cluster Headache
23 Avril 2019 - 5:10PM
Dow Jones News
By Colin Kellaher
Teva Pharmaceutical Industries Ltd. (TEVA) on Tuesday said it is
ending clinical development of fremanezumab in cluster headaches
after determining a Phase 3 study in episodic cluster headaches was
unlikely to meet its primary endpoint.
The Israeli pharmaceutical company said it is also ending a
long-term safety study that was part of the Phase 3 program.
Teva last year discontinued a study arm of the program in
chronic cluster headaches for similar reasons.
The U.S. Food and Drug Administration in December approved
fremanezumab, marketed as Ajovy, for the preventive treatment of
migraine in adults. Teva earlier this month said the European
Commission granted similar approval for Ajovy.
Teva said it will continues to explore other uses for
fremanezumab, including the treatment of post-traumatic
headache.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 23, 2019 10:55 ET (14:55 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
